ClinicalTrials.gg
TerminatedNCT04069260Updated May 27, 2020

A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis

A Phase 2 interventional study of ELX-02 in Genetic Disease, Nonsense Mutation and Cystinosis, sponsored by Eloxx Pharmaceuticals, Inc.. Terminated at 1 site in Canada. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-05-27.

Primary conditionCystinosisRegistry: Genetic Diseases, InbornReclassifiedWhy we changed it
Registry
Genetic Diseases, Inborn — the first condition term the registry derived for this study.
ClinicalTrials.gg
Cystinosis
Why
  1. The study's listed conditions name Cystinosis, a narrower term within Genetic Diseases, Inborn.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eloxx Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Due to study design limitations, this study has been discontinued and will not proceed with the 2nd cohort as contemplated in the original protocol.

From the registry’s dates

  • Primary completion was Dec 2019, 6 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Study summary

This is a Phase 2 open label study to evaluate the safety, tolerability, PK, and PD of multiple dose levels of SC administered ELX-02 in patients with cystinosis with nonsense mutation in at least one allele.

Six patients will be enrolled in the trial.

The study will comprise of the following periods for each patient:

  • A screening period of up to 6 weeks
  • A total treatment period of 4 weeks
  • A safety follow-up period of 4 weeks after the last treatment

Each patient will receive three escalating doses as follows:

  • Treatment period 1: ELX-02 0.5 mg/kg SC daily for 7 days (total dose not to exceed 3.5 mg/kg for this week; the daily dose will be individualized to achieve the target weekly exposure of about 47.5 µg*h/mL)
  • Treatment period 2: ELX-02 1.0 mg/kg SC daily for 7 days (total dose not to exceed 7.0 mg/kg for this week; the daily dose will be individualized to achieve the target weekly exposure of about 95 µg*h/mL)
  • Treatment period 3: ELX-02 2.0 mg/kg SC daily for 14 days (total dose not to exceed 14 mg/kg for these two weeks; the daily dose will be individualized to achieve the target weekly exposure of about 190 µg*h/mL)
02

Conditions studied

  • Genetic Disease
  • Nonsense Mutation
  • Cystinosis

Browse trials for

Keywords

  • aminoglycoside
  • translational read-through
  • cystinosis
  • nonsense mutation
03

In context

Cystinosis Reclassified

47 studies on the registry are indexed under Cystinosis; 15 are open to participants now.

This study's enrollment of 3 is below the median of 30 across 27 interventional studies indexed under Cystinosis.

Browse Cystinosis studies →

Lead sponsor

Eloxx Pharmaceuticals, Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Compared within Cystinosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Genetic Diseases, Inborn. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patients must meet all of the following criteria to participate in this study:

  1. Male or female patients who, at the time of screening, are 18 years of age or older (Cohort 1) or ≥12 years of age (Cohort 2)
  2. A diagnosis of nephropathic cystinosis and biallelic CTNS mutations, including at least one nonsense mutation
  3. Patients should have a mild to moderate disease estimated ≥40 mL/min/1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration CKD-EPI formula
  4. of 19.0 to 30.0 kg/m2. Patients with a lower BMI may be entered into the study at the discretion of the Investigator following consultation with the Sponsor
  5. Renal transplant permitted with stable graft function (serum creatinine) for 3 months prior to Screening

Patients with any of the following characteristics/conditions will not be included in the study:

  1. Participation in clinical study including administration of any drug or device in the last 30 days or 5 half-lives (whichever is longer) prior to investigational product dosing in the current study
  2. Concomitant use of cysteamine bitartrate from 7 days prior to baseline until 7 days following final administration ELX-02
  3. An average systolic blood pressure and/or diastolic blood pressure ≥95th percentile for sex, age, and height on 3 or more occasions during the screening period
  4. Patients without documented prior aminoglycoside exposure who have a mitochondrial mutation that has been shown to increase sensitivity to aminoglycosides
  5. Known relevant allergy or to aminoglycosides
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    ELX-02

    Eukaryotic ribosomal selective glycoside (ERSG)

    Drug: ELX-02

Interventions

  • DrugELX-02

    ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).

06

What researchers measure

Primary outcomes

  1. AEs associated with different dose levels of ELX-02

    Time frame: From the time of first dosing through the follow-up visit, an average of approximately 10 weeks

  2. Area under the plasma concentration curve from time zero to 24 hours (AUC0-24h)

    Full PK profile 12 blood samples over 24 hours

    Time frame: Day 1 of treatment periods 1, 2, and 3

  3. Maximum observed plasma concentration (Cmax)

    Full PK profile 12 blood samples over 24 hours

    Time frame: Day 1 of treatment periods 1, 2, and 3

  4. Observed plasma concentration at 1 hour post dose (C1h)

    Sparse sampling, blood sampling only, pre-dose and 1 hour post dose

    Time frame: Days 1, 2, 5, and 7 of treatment periods 1-2; Days 1, 2, 5, 7, 10, and 14 of treatment period 3

  5. Amount of ELX-02 excreted in urine from 0 to 24 hours (Ae24h)

    6 urine collections over 24 hours

    Time frame: Day 1 of treatment periods 1, 2, and 3

  6. Renal clearance on Day 1 (Ae24h/plasma AUC0-24h)

    6 urine collections over 24 hours

    Time frame: Day 1 of treatment periods 1, 2, and 3

Secondary outcomes

  1. Changes from baseline in WBC cystine levels

    Time frame: Screening; Days 1, 2, 5, and 7 of treatment periods 1-2; Days 1, 2, 5, 7, 10, and 14 of treatment period 3, and 4-week safety follow-up

07

Study locations

1 site
  • McGill University Health Center
    Montréal, Quebec H3H 2R9, Canada
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Dec 2019, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2019
First posted
Aug 28, 2019
StartActual
Aug 2, 2019
Primary completionActual
Dec 17, 2019
CompletionActual
Dec 17, 2019
Last update
May 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04069260
Lead sponsor
Eloxx Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Aug 28, 2019
Start date
Aug 2, 2019
Primary completion
Dec 17, 2019
Completion
Dec 17, 2019
Last update
May 27, 2020

Study contacts

Paul Goodyer, MD
principal investigator · McGill University

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ELX-02

Start the discussion